Clinical trial · no report yet · Phase 3
NCT05814354
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
- NCT05814354 ↗
- Active, not recruiting
- Jiangsu HengRui Medicine Co., Ltd.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 27 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- SHR-A1811; Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
- Arms
- SHR-A1811 · Experimental
- Physician's Choice · Active comparator
- Enrollment
- 551
- Primary outcomes
- Progression-free Survival (PFS) Based on Blind Independent Video Review Committee (BIRC)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Start
- Jun 30, 2023
- Primary completion
- Mar 20, 2026
- Results posted
- No
- Registry record
- NCT05814354 · updated Aug 6, 2026